Showing results (5681-5690 of 5,703) with videos related to

Sort By:
Pageof 571
The Oncologist|August 8, 2026
Association of SGLT2 Inhibitor Use with Clinical Outcomes in Patients Receiving Immune Checkpoint Inhibitors: A Pan-Tumor Propensity-Matched AnalysisSean C Dougherty, Sara Young, Hector Picon, et al.
The Oncologist|August 13, 2026
Immunohistochemistry-based molecular subtypes and stromal tumor-infiltrating lymphocytes in triple-negative breast cancer: a chemotherapy-only cohortJesus Edgardo Hernandez-Hernandez, Alejandro Mohar, César Octavio Lara-Torres, et al.
The Oncologist|August 14, 2026
Neoadjuvant chemotherapy in women with triple-negative breast cancer: Real world results from western KenyaHussain I Rangoonwala, Naftali Busakhala, Hillary Kiprono, et al.
The Oncologist|August 25, 2026
Real-world efficacy and toxicity of tebentafusp in metastatic uveal melanoma patients treated on the United Kingdom expanded access programmeMagdalene Joseph, Jacob Tharakan, Jemma Proudfoot-Jones, et al.
The Oncologist|September 7, 2026
Socioeconomic disparities in sarcoma diagnosis, expert center access, and advocacy group awareness: a multicenter study in Southern EuropePau Mascaró-Baselga, Víctor Navarro, Ana Sebio, et al.
The Oncologist|September 9, 2026
Real-world treatment landscape and clinical outcomes in first-line advanced or metastatic gastroesophageal adenocarcinoma in the United StatesJin Gu, Shivani K Mhatre, Daniel O Koralek, et al.
The Oncologist|September 9, 2026
Central Nervous System Symptom Burden and Clinical Implications for Antiemetic Management with Olanzapine in AC ChemotherapyRyoko Udagawa, Mototsugu Shimokawa, Hirotoshi Iihara, et al.
The Oncologist|September 3, 2026
Nilotinib revisited in GIST: Salvage use in patients with severe imatinib toxicityJohanna Falkenhorst, Peter Hohenberger, Giorgia Mancino, et al.
The Oncologist|September 12, 2026
The insufficient publication of early-phase clinical trials in oncologyMerel J J Lucassen, Tim Schutte, Alwin D R Huitema, et al.
The Oncologist|September 15, 2026
Real-world use of tafasitamab for relapsed or refractory diffuse large B-cell lymphoma among racial and ethnic minorities in the United StatesNarendranath Epperla, Loretta J Nastoupil, Bruce Feinberg, et al.
Pageof 571